GO:0051443 positive regulation of ubiquitin-protein transferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0051443 describes any process that activates, maintains, or increases the rate of ubiquitin transferase (E3 ligase) activity, thereby amplifying ubiquitin conjugation to substrate proteins.
• Positive regulation of ubiquitin-protein transferase activity is essential for selective protein degradation, DNA repair, cell cycle progression, mitophagy, and immune signaling.
• Key activators include SIRT6, TRIM25, Parkin, and UFL1, which modulate E3 ligases through post-translational modifications, complex assembly, or substrate recruitment.
• Dysregulation of this process contributes to cancer, atherosclerosis, sepsis, myocardial hypertrophy, and neurodegenerative disorders.
• CRISPR knockout, point-mutation knock-in, and overexpression models are powerful tools to dissect causal roles of E3 ligase regulators in disease.
• Understanding GO:0051443 provides a framework for targeting ubiquitin transferase activation in therapeutic development and biomarker discovery.
Description
Ubiquitination is a reversible post-translational modification that controls protein stability, localization, and function. The transfer of ubiquitin to substrate proteins is catalyzed by a hierarchical enzymatic cascade culminating in ubiquitin-protein transferases (E3 ligases). The Gene Ontology term GO:0051443, positive regulation of ubiquitin-protein transferase activity, captures any process that activates, maintains, or increases the rate of this final transfer step. This regulatory node is critical because it determines which proteins are tagged for degradation or altered signaling, thereby influencing cell fate decisions. Researchers study GO:0051443 to understand how cells rapidly remodel their proteome in response to stress, immune challenges, or metabolic cues. For example, SIRT6 protects smooth muscle cells from senescence by promoting ubiquitin transferase activity, linking this process to atherosclerosis. Similarly, TRIM25 enhances hepatocellular carcinoma survival by activating Keap1-Nrf2 signaling through ubiquitin transferase regulation. These examples underscore the broad physiological and pathological relevance of positive regulation of ubiquitin-protein transferase activity.
positive regulation of ubiquitin-protein transferase activity At A Glance
| GO ID | GO:0051443 |
|---|---|
| GO term | positive regulation of ubiquitin-protein transferase activity |
| Ontology | biological_process |
| Synonym | activation of ubiquitin transferase activity; APC activator; SCF complex activator; up regulation of ubiquitin ligase activity |
| Major function | Enhances the rate of ubiquitin transfer to substrate proteins by E3 ligases |
| Biological context | Protein degradation, cell cycle, DNA repair, mitophagy, immune signaling |
| Key regulators | SIRT6, TRIM25, Parkin, UFL1, and other E3 ligase modulators |
| Disease relevance | Cancer, atherosclerosis, sepsis, myocardial hypertrophy, neurodegeneration |
What Is GO:0051443?
GO:0051443 is defined as any biological process that activates, maintains, or increases the rate of ubiquitin transferase activity. In practical terms, it encompasses molecular events such as allosteric activation of E3 ligases, post-translational modifications that enhance their catalytic efficiency, recruitment of E2 conjugating enzymes, or stabilization of multi-subunit E3 complexes. This term does not describe the ubiquitination reaction itself but rather the upstream or intrinsic regulatory inputs that boost the capacity of ubiquitin-protein transferases to conjugate ubiquitin to substrates.
Why Is positive regulation of ubiquitin-protein transferase activity Important in Cell Biology?
Positive regulation of ubiquitin-protein transferase activity is a central control point in the ubiquitin-proteasome system. By modulating E3 ligase activity, cells can rapidly and selectively degrade or alter the function of key regulatory proteins, thereby driving processes such as cell cycle progression, apoptosis, mitophagy, and immune responses. Dysregulation of this process is implicated in a wide range of human diseases, including cancer, cardiovascular disorders, and inflammatory conditions. Therefore, understanding the mechanisms that positively regulate ubiquitin transferase activity offers opportunities for therapeutic intervention and biomarker development.
• Controls selective protein degradation and turnover, impacting nearly every cellular pathway.
• Regulates cell cycle progression by activating anaphase-promoting complex (APC) and SCF complexes.
• Modulates mitophagy and mitochondrial quality control through Parkin activation.
• Influences immune signaling and inflammation via NLRP3 and NF-kB pathways.
• Plays a role in DNA damage response and genome stability.
• Contributes to cancer progression by stabilizing oncoproteins or degrading tumor suppressors.
• Implicated in cardiovascular diseases such as atherosclerosis and myocardial hypertrophy.
• Provides targets for small-molecule activators or inhibitors of E3 ligases.
• Essential for neuronal health and implicated in neurodegeneration.
• Enables rapid cellular adaptation to stress and metabolic changes.
What Happens During positive regulation of ubiquitin-protein transferase activity?
Activation of E3 Ligase Complexes
In simple terms: Cells switch on the enzymes that attach ubiquitin to target proteins.
Positive regulation of ubiquitin-protein transferase activity often begins with the assembly or conformational activation of multi-subunit E3 ligase complexes such as SCF (Skp1-Cullin-F-box) or APC/C. For instance, SIRT6 promotes ubiquitin transferase activity in smooth muscle cells, protecting them from senescence. Similarly, TRIM25, a RING-type E3 ligase, is positively regulated to enhance its catalytic activity toward Keap1, leading to Nrf2 stabilization.
Post-Translational Modifications of E3 Ligases
In simple terms: Chemical tags on the ubiquitin enzyme can make it more active.
Phosphorylation, ubiquitination, and SUMOylation of E3 ligases can increase their activity. For example, the RAB7A phosphoswitch coordinates Rubicon Homology protein regulation of Parkin-dependent mitophagy, highlighting how phosphorylation events positively regulate Parkin's ubiquitin transferase activity. UFL1, a UFM1 ligase, is targeted by PARP1 to modulate its activity, linking PARP1 to positive regulation of ubiquitin transferase activity.
Substrate Recruitment and Allostery
In simple terms: Bringing the target protein close to the enzyme speeds up ubiquitin transfer.
Adaptor proteins can enhance E3 ligase activity by recruiting specific substrates. For instance, circNDUFB2 destabilizes IGF2BPs by promoting their ubiquitination, likely through positive regulation of the responsible E3 ligase. Allosteric changes in the E3 ligase upon substrate binding can also increase catalytic turnover, as seen in APC/C activation during mitosis.
Integration with Cellular Stress and Immune Signals
In simple terms: Stress and immune alarms can boost ubiquitin tagging.
Hypoxia-induced inflammatory cell death in cancer involves positive regulation of ubiquitin transferase activity, as hypoxia can trigger E3 ligase activation. In sepsis, GITR exacerbates macrophage pyroptosis by post-translationally regulating NLRP3, a process that may involve enhanced ubiquitin transferase activity. These examples illustrate how environmental and immune cues converge on E3 ligase activation.
Key Genes Involved in GO:0051443 positive regulation of ubiquitin-protein transferase activity
The following genes and proteins are experimentally validated regulators or effectors of positive regulation of ubiquitin-protein transferase activity (GO:0051443).
| Gene | Major Role | Research Relevance |
|---|---|---|
| SIRT6 | Promotes ubiquitin transferase activity, protects smooth muscle cells from senescence | Atherosclerosis, aging |
| TRIM25 | RING-type E3 ligase, positively regulates Keap1-Nrf2 pathway | Hepatocellular carcinoma |
| Parkin (PRKN) | E3 ligase activated by phosphorylation, drives mitophagy | Neurodegeneration, mitophagy |
| UFL1 | UFM1 ligase, interacts with PARP1 to modulate ubiquitin transferase activity | Anti-tumor immunity |
| NLRP3 | Inflammasome component, regulated by ubiquitination | Sepsis, inflammation |
| IGF2BP | RNA-binding protein destabilized by ubiquitination | Non-small cell lung cancer |
| APC/C | Multi-subunit E3 ligase activated during mitosis | Cell cycle, cancer |
| SCF complex | Multi-subunit E3 ligase activated by neddylation | Cell cycle, signaling |
| Keap1 | Substrate adaptor for Cullin3-based E3 ligase | Cancer, oxidative stress |
| Nrf2 | Transcription factor stabilized upon Keap1 ubiquitination | Cancer, inflammation |
| ACSL4 | Lipid metabolism enzyme regulated by ubiquitination | Myocardial hypertrophy |
| AMPK | Kinase that can modulate E3 ligase activity | Metabolism, mitophagy |
| Rubicon | Regulator of Parkin-dependent mitophagy | Mitophagy, neurodegeneration |
| RAB7A | GTPase with phosphoswitch controlling Parkin regulation | Mitophagy |
| GITR | Immune checkpoint, regulates NLRP3 ubiquitination | Sepsis |
| PARP1 | Poly(ADP-ribose) polymerase, modulates UFL1 activity | Anti-tumor immunity |
| circNDUFB2 | Circular RNA that promotes ubiquitination of IGF2BPs | Non-small cell lung cancer |
How Is positive regulation of ubiquitin-protein transferase activity Regulated?
Positive regulation of ubiquitin-protein transferase activity is itself tightly regulated at multiple levels. Upstream kinases such as AMPK can phosphorylate E3 ligases or their adaptors to enhance activity. Neddylation of Cullin subunits in SCF complexes is a well-known mechanism that activates the ligase. Conversely, deubiquitinases can remove ubiquitin from E3 ligases and dampen their activity. In hypoxia, HIF signaling can induce E3 ligase expression or activity. Immune signals through GITR can post-translationally modify NLRP3, potentially affecting its ubiquitination. These regulatory layers ensure that ubiquitin transferase activity is spatiotemporally controlled.
positive regulation of ubiquitin-protein transferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SIRT6 | Atherosclerosis | Smooth muscle cell-specific KO mouse |
| TRIM25 | Hepatocellular carcinoma | Xenograft with TRIM25 overexpression |
| Parkin (PRKN) | Parkinson's disease, mitophagy | PRKN knockout neurons, point-mutation knock-in |
| UFL1 | Anti-tumor immunity | UFL1 knockout tumor models |
| NLRP3 | Sepsis | NLRP3 knock-in mice, macrophage-specific KO |
Cancer
Positive regulation of ubiquitin-protein transferase activity is frequently hijacked in cancer. TRIM25 promotes hepatocellular carcinoma cell survival by enhancing Keap1 ubiquitination and Nrf2 activation. circNDUFB2 inhibits non-small cell lung cancer progression by destabilizing IGF2BPs through ubiquitination. Targeting the UFL1-PARP1 axis amplifies anti-tumor immunity, suggesting that modulating ubiquitin transferase activity can boost immunotherapy. Hypoxia-induced inflammatory cell death in cancer also involves E3 ligase activation.
Cardiovascular Diseases
SIRT6 protects smooth muscle cells from senescence and reduces atherosclerosis by promoting ubiquitin transferase activity. Paeoniflorin mitigates myocardial hypertrophy by regulating mitophagy and ferroptosis via the AMPK-Parkin-ACSL4 pathway, which involves Parkin activation. These findings link positive regulation of ubiquitin-protein transferase activity to cardiovascular protection.
Inflammatory and Infectious Diseases
In sepsis, GITR exacerbates lysophosphatidylcholine-induced macrophage pyroptosis by post-translationally regulating NLRP3, a process that may involve ubiquitination. Hypoxia-induced inflammatory cell death in cancer also highlights the role of E3 ligases in inflammation. Modulating ubiquitin transferase activity could therefore be a therapeutic strategy in inflammatory conditions.
Neurodegeneration
Parkin is a key E3 ligase whose activation is positively regulated by phosphorylation and RAB7A phosphoswitch, driving mitophagy. Defects in Parkin activation are linked to Parkinson's disease and other neurodegenerative disorders. Thus, understanding GO:0051443 is critical for developing neuroprotective therapies.
From positive regulation of ubiquitin-protein transferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SIRT6 positively regulate ubiquitin transferase activity in atherosclerosis? | SIRT6 knockout and overexpression in smooth muscle cells |
| How does TRIM25 activation affect Keap1-Nrf2 signaling in liver cancer? | TRIM25 knockout and point-mutation knock-in in HCC cell lines |
| What is the role of Parkin phosphorylation in mitophagy? | Parkin point-mutation knock-in (e.g., S65A) in neurons |
| Can UFL1-PARP1 axis modulation enhance anti-tumor immunity? | UFL1 knockout and PARP1 inhibitor in tumor models |
| How does circNDUFB2 regulate IGF2BP ubiquitination? | circNDUFB2 overexpression and knockout in NSCLC cells |
| Does GITR regulate NLRP3 ubiquitination in sepsis? | GITR knockout and NLRP3 tagged knock-in macrophages |
How to Study the positive regulation of ubiquitin-protein transferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| In vitro ubiquitination assay | Rate of ubiquitin transfer | Enzyme kinetics, activator screening |
| Mass spectrometry | Ubiquitinated substrates and chain types | Substrate identification |
| CRISPR knockout screen | Genes required for ubiquitin transferase activity | Pathway discovery |
| RNA-seq | Transcriptional changes upon E3 ligase modulation | Downstream effects |
| Proximity ligation assay | Protein-protein interactions | E3 ligase-substrate binding |
| Live-cell imaging | Spatiotemporal dynamics of ubiquitination | Mitophagy, cell cycle |
| Co-immunoprecipitation | Complex formation | E3 ligase complex assembly |
| Phospho-proteomics | Signaling changes | Upstream regulation |
Ubiquitination Assays
In vitro ubiquitination assays using recombinant E1, E2, E3, and substrate proteins can directly measure the rate of ubiquitin transfer. These assays are often combined with ATP and ubiquitin-7-amido-4-methylcoumarin to monitor activity. For example, SIRT6-mediated activation of ubiquitin transferase was demonstrated using such assays.
Proteomics and Mass Spectrometry
Mass spectrometry-based proteomics can identify ubiquitinated substrates and quantify changes in ubiquitin chain topology upon E3 ligase activation. This approach has been used to map TRIM25-dependent ubiquitination of Keap1 and Parkin substrates in mitophagy.
CRISPR Screens and Functional Genomics
Genome-wide CRISPR knockout or activation screens can identify genes that positively regulate ubiquitin transferase activity. For instance, screens have uncovered regulators of NLRP3 ubiquitination and modulators of anti-tumor immunity.
Imaging and Live-Cell Analysis
Fluorescently tagged ubiquitin and E3 ligases enable real-time imaging of ubiquitin transfer in live cells. This has been used to study Parkin recruitment to mitochondria during mitophagy and APC/C dynamics during mitosis.
How CRISPR Can Be Used to Study GO:0051443 positive regulation of ubiquitin-protein transferase activity
Knockout
CRISPR knockout of genes encoding E3 ligases or their regulators can abolish positive regulation of ubiquitin-protein transferase activity. For example, SIRT6 knockout in smooth muscle cells reduces ubiquitin transferase activity and accelerates senescence. TRIM25 knockout in hepatocellular carcinoma cells impairs Keap1 ubiquitination and Nrf2 activation.
Point Mutation
Point mutations can be introduced to mimic or abolish phosphorylation sites on E3 ligases. For instance, Parkin S65A knock-in prevents activation and mitophagy. Such models are invaluable for dissecting the precise residues required for positive regulation.
Knock-in
Tagged knock-in of E3 ligases (e.g., HA- or GFP-tagged) allows for endogenous tracking and interaction studies. Knock-in of disease-associated mutations can model human disorders. For example, NLRP3 knock-in mice can be used to study sepsis.
Overexpression
Overexpression of E3 ligases or their activators can enhance ubiquitin transferase activity. TRIM25 overexpression promotes HCC growth, while circNDUFB2 overexpression destabilizes IGF2BPs and inhibits NSCLC. Overexpression models are useful for gain-of-function studies.
How EDITGENE Supports positive regulation of ubiquitin-protein transferase activity Research
Researchers studying positive regulation of ubiquitin-protein transferase activity-related genes often need to determine whether a candidate gene is causally involved in a specific biological process or disease. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling functional validation and mechanistic dissection.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of ubiquitin-protein transferase activity research.
Frequently Asked Questions About positive regulation of ubiquitin-protein transferase activity
What is GO:0051443?
GO:0051443 is the Gene Ontology term for positive regulation of ubiquitin-protein transferase activity, describing any process that activates, maintains, or increases the rate of ubiquitin transfer to substrate proteins.
What genes are involved in positive regulation of ubiquitin-protein transferase activity?
Key genes include SIRT6, TRIM25, Parkin (PRKN), UFL1, and components of the APC/C and SCF complexes.
How is ubiquitin-protein transferase activity regulated?
It is regulated by post-translational modifications (e.g., phosphorylation, neddylation), allosteric changes, and adaptor proteins that recruit substrates.
What diseases are associated with dysregulation of GO:0051443?
Cancer, atherosclerosis, sepsis, myocardial hypertrophy, and neurodegenerative disorders such as Parkinson's disease.
What experimental methods are used to study positive regulation of ubiquitin-protein transferase activity?
Common methods include in vitro ubiquitination assays, mass spectrometry, CRISPR screens, live-cell imaging, and co-immunoprecipitation.
How can CRISPR be used to study GO:0051443?
CRISPR knockout, point mutation knock-in, and overexpression models allow researchers to dissect the causal roles of E3 ligases and their regulators.
What is the role of SIRT6 in ubiquitin transferase activity?
SIRT6 promotes ubiquitin transferase activity in smooth muscle cells, protecting them from senescence and reducing atherosclerosis.
How does TRIM25 regulate ubiquitin transferase activity?
TRIM25 is a RING-type E3 ligase that positively regulates Keap1 ubiquitination, leading to Nrf2 activation and hepatocellular carcinoma survival.
What is the connection between Parkin and mitophagy?
Parkin is an E3 ligase activated by phosphorylation; its positive regulation drives mitophagy, and defects are linked to neurodegeneration.
Why is positive regulation of ubiquitin-protein transferase activity important for cancer research?
It controls the stability of oncoproteins and tumor suppressors; targeting this process can inhibit tumor growth or enhance immunotherapy.
Conclusion
Positive regulation of ubiquitin-protein transferase activity (GO:0051443) is a fundamental biological process that governs protein degradation, cell cycle, mitophagy, and immune signaling. Its dysregulation is implicated in cancer, cardiovascular diseases, inflammation, and neurodegeneration. By leveraging CRISPR-based models and advanced screening technologies, researchers can uncover novel regulators and therapeutic targets within this pathway. EDITGENE provides the tools and expertise to accelerate these discoveries.
References
- 1. Grootaert MOJ et al.. 2021. SIRT6 Protects Smooth Muscle Cells From Senescence and Reduces Atherosclerosis.. Circ Res 128(4):474-491 PMID: 33353368
- 2. Li B et al.. 2021. circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity.. Nat Commun 12(1):295 PMID: 33436560
- 3. Wang Y et al.. 2026. Paeoniflorin mitigates myocardial hypertrophy by regulating mitophagy and ferroptosis mediated by mitochondria-associated AMPK-Parkin-ACSL4 pathway.. Free Radic Biol Med 245:98-114 PMID: 41443335
- 4. Bhardwaj A et al.. 2025. A mechanism for hypoxia-induced inflammatory cell death in cancer.. Nature 637(8045):470-477 PMID: 39506105
- 5. Song W et al.. 2025. Targeting the UFL1-PARP1 axis amplifies anti-tumor immunity.. Cell Rep 44(10):116433 PMID: 41105513
- 6. Liang S et al.. 2024. GITR exacerbates lysophosphatidylcholine-induced macrophage pyroptosis in sepsis via posttranslational regulation of NLRP3.. Cell Mol Immunol 21(7):674-688 PMID: 38740925
- 7. Liu Y et al.. 2020. TRIM25 promotes the cell survival and growth of hepatocellular carcinoma through targeting Keap1-Nrf2 pathway.. Nat Commun 11(1):348 PMID: 31953436
- 8. Tudorica DA et al.. 2024. A RAB7A phosphoswitch coordinates Rubicon Homology protein regulation of Parkin-dependent mitophagy.. J Cell Biol 223(7) PMID: 38728007
